30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: LDR

4Q13 revenue: $32.0MM, +28% (U.S. $24.9MM, +37%; ex-U.S. $7.1MM, +4%)

  • Traditional Fusion $4.5MM, +5%
  • Exclusive Technologies $27.5MM, +33% (Cervical $17.5MM, +32%; Lumbar $10MM, +35%)

 

  • Growth primarily attributed to Mobi-C, Avenue L lateral fusion interbody device, ROI-A

 

2013 revenue: of $111.6MM, +23% (U.S. $82.3MM, +27%; ex-U.S. $29.2MM, +12%)

  • Traditional Fusion $18.8MM, +4%
  • Exclusive Technologies $92.8MM, +28%

 

  • 190+ U.S. sales agencies in place, >80% exclusive for at least 3 of 4 Exclusive Technologies
  • 650+ surgeons trained to date on Mobi-C (was expecting 400 to 500)
  • Seeing less Mobi-C cannibalization of ROI-C than expected
  • Mobi-C proving to be excellent entry to new customers
  • Presenting 5-year clinical data on Mobi-C by year-end, currently sharing data with payers

 

2014 forecast: $128MM-$130MM, 15% to 16% growth